share_log

Grail | 8-K: Current report

Grail | 8-K: Current report

Grail | 8-K:重大事件
美股SEC公告 ·  2024/10/23 05:13

Moomoo AI 已提取核心信息

Grail announced the appointment of Sarah Krevans to its Board of Directors effective October 21, 2024. Krevans will serve as a Class II director until 2026 and join the Board's Audit, Compensation, and Nominating and Governance committees. The appointment expands the Board to five directors, with four being independent.As the former President and CEO of Sutter Health from 2016 to 2022, Krevans led an integrated network of 14,000 clinicians and 24 hospitals, advancing clinical programs and digital health initiatives. Her compensation includes a $50,000 annual cash retainer for Board service, additional committee retainers, and an initial grant of 31,055 restricted stock units vesting over three years.Krevans brings extensive healthcare leadership experience, having previously served as COO at Sutter Health and held executive positions at Kaiser Permanente. She holds master's degrees from UC Berkeley and has been recognized among Modern Healthcare's "Top 25 Women Leaders" and "100 Most Influential People in Healthcare."
Grail announced the appointment of Sarah Krevans to its Board of Directors effective October 21, 2024. Krevans will serve as a Class II director until 2026 and join the Board's Audit, Compensation, and Nominating and Governance committees. The appointment expands the Board to five directors, with four being independent.As the former President and CEO of Sutter Health from 2016 to 2022, Krevans led an integrated network of 14,000 clinicians and 24 hospitals, advancing clinical programs and digital health initiatives. Her compensation includes a $50,000 annual cash retainer for Board service, additional committee retainers, and an initial grant of 31,055 restricted stock units vesting over three years.Krevans brings extensive healthcare leadership experience, having previously served as COO at Sutter Health and held executive positions at Kaiser Permanente. She holds master's degrees from UC Berkeley and has been recognized among Modern Healthcare's "Top 25 Women Leaders" and "100 Most Influential People in Healthcare."
Grail宣布任命Sarah Krevans为其董事会成员,任命自2024年10月21日起生效。Krevans将担任二级董事,任期至2026年,并加入董事会的审计、薪酬以及提名和治理委员会。此次任命使董事会扩展至五名董事,其中四名为独立董事。作为2016年至2022年Sutter Health的前任总裁兼首席执行官,Krevans领导着一个由14,000名临床医生和24家医院组成的综合网络,推动临床项目和互联网医疗倡议。她的薪酬包括董事会服务的每年50,000美元现金保留金,额外的委员会保留金,以及初始授予31,055个限制性股票单位,这些股票将在三年内逐步解禁。Krevans拥有丰富的医疗领导经验,曾担任Sutter Health的首席运营官,并在凯泽永久担任过高管职位。她拥有加州大学伯克利分校的硕士学位,并被现代医疗评选为“25位杰出女性领导者”和“100位最具影响力的医疗人物”之一。
Grail宣布任命Sarah Krevans为其董事会成员,任命自2024年10月21日起生效。Krevans将担任二级董事,任期至2026年,并加入董事会的审计、薪酬以及提名和治理委员会。此次任命使董事会扩展至五名董事,其中四名为独立董事。作为2016年至2022年Sutter Health的前任总裁兼首席执行官,Krevans领导着一个由14,000名临床医生和24家医院组成的综合网络,推动临床项目和互联网医疗倡议。她的薪酬包括董事会服务的每年50,000美元现金保留金,额外的委员会保留金,以及初始授予31,055个限制性股票单位,这些股票将在三年内逐步解禁。Krevans拥有丰富的医疗领导经验,曾担任Sutter Health的首席运营官,并在凯泽永久担任过高管职位。她拥有加州大学伯克利分校的硕士学位,并被现代医疗评选为“25位杰出女性领导者”和“100位最具影响力的医疗人物”之一。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息